Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · IEX Real-Time Price · USD
28.93
-0.30 (-1.03%)
At close: Apr 25, 2024, 4:00 PM
28.16
-0.77 (-2.66%)
After-hours: Apr 25, 2024, 5:48 PM EDT
Company Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Dr. Jeffrey M. Dayno M.D. |
Contact Details
Address: 630 W Germantown Pike, Suite 215 Plymouth Meeting, Pennsylvania 19462 United States | |
| Phone | (484) 539-9800 |
| Website | harmonybiosciences.com |
Stock Details
| Ticker Symbol | HRMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001802665 |
| CUSIP Number | 413197104 |
| ISIN Number | US4131971040 |
| Employer ID | 82-2279923 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey S. Aronin | Founder and Non-Executive Chairman |
| Dr. Jeffrey M. Dayno M.D. | President, Chief Executive Officer and Director |
| Sandip S. Kapadia C.P.A., M.B.A. | Executive Vice President, Chief Administrative Officer and Chief Financial Officer |
| Jeffrey Dierks M.B.A. | Executive Vice President and Chief Commercial Officer |
| Andrew Serafin J.D., M.B.A. | Executive Vice President and Chief Strategy Officer |
| David Bradshaw | Head of Technical Operations |
| Luis Sanay | Head of Investor Relations |
| Christian Ulrich | General Counsel and Corporate Secretary |
| Tricia Glover | Chief Compliance Officer |
| Audrey Murphy SPHR | Head of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | ARS | Filing |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 15, 2024 | 144 | Filing |
| Mar 8, 2024 | 144 | Filing |
| Feb 28, 2024 | 10-K/A | [Amend] Annual report |
| Feb 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |